Showing results (571-580 of 617) with videos related to

Sort By:
Pageof 62
Bone Marrow Transplantation|June 13, 2000
High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancerM L Donato, D Gershenson, C Ippoliti, et al.
The New England Journal of Medicine|January 20, 2006
Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndromeKathleen M Schmeler, Henry T Lynch, Lee-may Chen, et al.
Gynecologic Oncology|September 12, 2024
Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14Jubilee Brown, Austin Miller, Laura L Holman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2004
Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapyMory Nouriani, Afshin Bahador, Jonathan S Berek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2004
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysisKaren H Lu, Andrea P Patterson, Lin Wang, et al.
Cancer Biology & Therapy|September 10, 2009
Anti-angiogenic properties of metronomic topotecan in ovarian carcinomaWilliam M Merritt, Christopher G Danes, Mian M K Shahzad, et al.
Gynecologic Oncology|April 22, 2019
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumorMartin Gore, Allan Hackshaw, William E Brady, et al.
Gynecologic Oncology|November 28, 2017
Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 StudyNeil S Horowitz, G Larry Maxwell, Austin Miller, et al.
Gynecologic Oncology|April 6, 2024
High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinomaRobert L Hollis, Richard Elliott, John C Dawson, et al.
Gynecologic Oncology|November 24, 2022
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancerShannon N Westin, Siqing Fu, Apostolia Tsimberidou, et al.
Pageof 62